Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Firefly molecule could quickly shed light on how well new drugs work

18.12.2002


Faint glow given off only when cells are killed could speed drug development for cancer, stroke, other diseases



The process that makes fireflies glow bright in the summer night can also shed light on how well new medicines work, showing immediately whether the drugs are effective at killing cells or causing other effects.

That’s the conclusion of a team of scientists from the University of Michigan Health System, who report that they have inserted the gene for a firefly’s glow-producing molecule into mice with cancer, and kept it from producing its telltale beacon of light until the cells started to die in response to cancer treatment.


Using a highly sensitive camera, the researchers were able to immediately detect the faintest traces of the firefly light as it passed outside the bodies of the mice.

The findings, published in the Dec. 24 issue of the Proceedings of the National Academy of Sciences and posted online last week, promises to give researchers a new way to get real-time information on whether new medicines are working.

It could be used to speed up the testing of new drugs for cancer, stroke, AIDS, auto-immune disorders, blood diseases, heart attack damage, nerve-degenerative diseases like Alzheimer’s disease, and other disorders where drugs are needed to kill cells, or to stop cell death. It could also be used to monitor other cell processes.

"This is the first time anyone has been able to make real-time images of apoptosis -- the process of cell death that is so important to so many diseases and treatments," says lead author Alnawaz Rehemtulla, Ph.D., associate professor of radiation oncology at the U-M Medical School and co-director of the U-M Center for Molecular Imaging. "This proves that we can see what’s going on at the molecular level while the drugs are working, giving results in days or weeks instead of months or years.’

The process is made possible through the use of luciferase, the enzyme that triggers a chemical process that lights up the tails of fireflies. The light-emitting process, called bioluminescence, has been used for several years in biomedical research -- but with the glow always turned "on" to produce a constant stream of light.

The U-M team, led by Rehemtulla and Brian D. Ross, Ph.D., professor of radiology and co-director of the center, reports they have discovered a way to turn the light "off" until a drug causes a cell to start dying.

They did this by attaching luciferase to another protein, a portion of the receptor for the hormone estrogen. The estrogen receptor, or ER, is known to squelch the action of attached proteins, such as luciferase’s light-releasing chemical reaction.

Then, they added a "switch" that could turn the luciferase on -- but only when the cell was in the self-destruction process called apoptosis.

The ability to make images of apoptosis in real time could help pharmaceutical companies and academic researchers screen new drugs rapidly, for all types of diseases that are characterized by over-growing cells – or cells that die too soon.

For example, scientists are studying drugs that can keep brain cells from dying after a stroke, a process that occurs through apoptosis and can cause permanent disability. Conversely, cancers and blood disorders that stem from over production of certain cell types are often treated with drugs aimed at killing extra cells.

But the U-M team believes its technique could also help with drug discovery and testing in diseases where other molecular mechanisms besides apoptosis are involved.

The team’s discovery hinges on the ability to turn the luciferase glow off until a cell process occurs. They developed this "light switch" by inserting a tiny section of protein between the luciferase and the estrogen receptor (ER) protein. Called DEVD, the section is known to be targeted for cutting by an enzyme called caspase-3 -- the key agent that sets off apoptosis. Because caspase-3 is most active when cells are dying, the team felt that it would cut the DEVD site on their luciferase-ER complex, allowing light to escape, if a cell-killing drug was working.

They were right. In the new report, the team shows that the luciferase-DEVD-ER complex released much less light than luciferase alone in either cell cultures or in mice with cancer that had been injected with a DNA sequence encoding the complex. When they added another ER and DEVD to the other side of the luciferase, the amount of light emitted was cut even further.

But when the researchers added an experimental cancer-fighting drug called TRAIL, which is known to cause apoptosis, it was just like turning on a light switch.

As the drug caused the activation of the caspase-3 enzyme, the bonds between the luciferase and its light-hiding companion ER molecules were cut at the DEVD cleavage site, and the light-emitting process began. One hour after TRAIL treatment, the amount of light emitted from the mice had gone up by 186 percent. Mice that received a placebo instead of TRAIL emitted only about 21 percent more light than they had before.

Even though only a few photons, or particles of light, can escape a mouse body from the glowing luciferase, the researchers were able to detect them with a bioluminescence imaging camera that can detect single photons.

The camera, which is kept in a light-proof chamber at ultra-cold temperatures to keep out all stray energy, produced vivid images showing the intensity of light -- and therefore the rate of cell death -- in different regions of the cell cultures or mouse cancer tumors. Rehemtullah notes that the technology is sensitive enough to pick up cell death in areas as small as 100 cells.

"The enzyme was turned on in a protease-dependent manner, and though we used caspase-3 in this instance, we believe it could be any protease that’s important to any cellular process," Ross emphasizes. "And, we believe other reporters could be used, including radioactive positron-emitting molecules that can be imaged using PET scanning." He noted that preliminary work on these approaches, and efforts to develop a transgenic strain of mice containing the genes for the luciferase complex, is already under way at UMHS.

The research was funded by the National institutes of Health through grants supporting the Center for Molecular Imaging, and by the Michigan Life Sciences Corridor.


The U-M has applied for a patent on the technique, and licensed it to a local biotechnology company, Molecular Therapeutics, Inc. Both Rehemtulla and Ross hold key positions at Molecular Therapeutics (www.moleculartherapeutics.com).

Other authors are former postdoctoral fellow Bharathi Laxman, Ph.D., research associate Daniel Hall, research fellow Mahaveer Swaroop Bhojani, radiation oncology resident Daniel Hamstra, and radiology professor Thomas Chenevert, Ph.D.

Reference: Proceedings of the National Academy of Sciences, Dec. 23, 2002, Vol. 99, No. 26, pp. 16551–16555 or www.pnas.org/cgi/content/abstract/252644499v1.

Kara Gavin | EurekAlert!
Further information:
http://www.pnas.org/cgi/content/abstract/252644499v1

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>